<DOC>
	<DOCNO>NCT01505179</DOCNO>
	<brief_summary>The purpose study determine whether treatment Ranolazine improve exercise capacity patient Heart Failure preserve leave ventricular ejection fraction .</brief_summary>
	<brief_title>The Effects Ranolazine Exercise Capacity Patients With Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description>Denise Barnard , M.D. , associate , conduct research study find way improve symptom patient Heart Failure Preserved Ejection Fraction ( HFPEF ) . Heart failure preserve ejection fraction condition heart squeeze well stiff . This stiffness heart muscle make heart unable fill , lead shortness breath decrease exercise tolerance . Subjects HFPEF ask participate study . There approximately 40 participant enrol study . The purpose study investigate effect Ranolazine ( Ranexa ) patient HFPEF . The study sponsor manufacturer drug , Gilead Pharmaceuticals . Ranolazine drug affect ion channel heart . In patient heart failure , ion channel work properly , contribute make heart stiff . A stiff heart lead symptom shortness breath patient HFPEF experience . Due property , Ranolazine may improve stiffness . Ranolazine could improve subject 's shortness breath ability exercise . Ranolazine approve patient suffer chest pain show help patient able exercise longer less chest pain . Ranolazine approve improvement exercise patient HFPEF . The investigator hope study whether Ranolazine help patient HFPEF study . To properly evaluate effect Ranolazine , research study set double blind , placebo control study . Subjects randomly assign ( like roll dice ) either Ranolazine placebo ( inactive substance ) . Subjects 50 % chance get study drug 50 % chance get placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
	<criteria>I . Inclusion Criteria Age &gt; 18 year old Diagnosis HFPEF : Signs symptom heart failure ( breathlessness , pulmonary congestion , edema , fatigue ) , NYHA Class IIIII CHF AND LVEF &gt; 45 % AND Evidence elevate LV fill pressure 1 . E/E'mitral &gt; 8 2 . BNP &gt; 80 pg/mL PA systolic pressure &gt; 35 mm Hg echocardiography Stable medical management least 1 month II . Exclusion Criteria Inability perform 6 minute walk test 6 minute walk distance &gt; 550 meter baseline Inability perform Naughton protocol exercise test , absolute contraindication exercise test Decompensated heart failure Clinically significant valvular disease congenital cardiac defect Clinical diagnosis COPD significant lung pathology Prior treatment ranolazine Percutaneous coronary intervention within past 6 month plan intervention study period Acute coronary syndrome within prior 2 month Presence uncorrected perfusion defect stress test Presence angina Any rhythm sinus QTc &gt; 500 msec Clinically significant hepatic impairment ( ALT/AST &gt; 3x upper limit normal ) Participation another investigational drug device study within 1 month prior screen Females childbearing potential Current treatment potent inhibitor CYP3A ( e.g . ketoconazole , itraconazole , clarithromycin , nefazodone , nelfinavir , ritonavir , indinavir , saquinavir ) Current treatment CYP3A PGP inducer ( e.g . rifampin , rifampicin , carbamazepine , St. John 's wort ) Any condition opinion investigator likely prevent compliance study protocol pose safety concern subject participates study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>HFPEF</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>HF w/ preserve EF</keyword>
	<keyword>Preserved EF</keyword>
	<keyword>Preserved Ejection Fraction</keyword>
	<keyword>Diastolic Dysfunction</keyword>
</DOC>